Related Experiment Videos
Recombinant erythropoietin reverses polymorphonuclear granulocyte dysfunction in iron-overloaded dialysis patients
J R Boelaert1, B F Cantinieaux, C F Hariga
1Unit for Renal and Infectious Diseases, Algemeen Ziekenhuis St Jan, Brugge, Belgium.
Abstract:
Iron overload increases the risk of bacterial infection in dialysis patients, partly by impairing functions of the polymorphonuclear granulocytes (PMNs). PMN defence was studied sequentially in haemodialysis patients with transfusional haemosiderosis, treated for 6 +/- 1.5 months (n = 8) to 13 +/- 1.7 months (n = 4) with recombinant human erythropoietin (rHuEpo). Over this period, signs of iron overload (increased serum ferritin and serum iron) improved, and stainable iron disappeared in PMNs. Simultaneously, phagocytosis of Yersinia enterocolitica by PMNs improved. The decrease in serum ferritin was significantly related to the improved phagocytosis. Killing of Y. enterocolitica by PMNs also improved. It is anticipated that rHuEpo therapy in iron-overloaded dialysis patients could decrease the incidence of bacterial infection by improving PMN functions in these patients.
Insights
Recombinant human erythropoietin (rHuEpo) therapy improved polymorphonuclear granulocyte (PMN) function in dialysis patients with iron overload. This enhancement in PMN defense may reduce bacterial infection risk in this vulnerable population.
Area of Science:
- Nephrology
- Immunology
- Hematology
Background:
- Iron overload is a significant risk factor for bacterial infections in dialysis patients.
- Impaired polymorphonuclear granulocyte (PMN) function contributes to this increased susceptibility.
- Transfusional haemosiderosis is a common complication in long-term dialysis patients.
Purpose of the Study:
- To investigate the sequential effects of recombinant human erythropoietin (rHuEpo) therapy on PMN function in dialysis patients with iron overload.
- To assess the relationship between iron overload markers and PMN phagocytic capacity.
- To evaluate the impact of rHuEpo on bacterial killing by PMNs.
Main Methods:
- Sequential study of haemodialysis patients (n=8 initially, n=4 at later time point) treated with rHuEpo for 6-13 months.
- Monitoring of iron overload markers: serum ferritin and serum iron.
- Assessment of PMN iron content via staining.
- Evaluation of PMN phagocytosis and killing of Yersinia enterocolitica.
Main Results:
- rHuEpo treatment led to improvement in iron overload markers, including decreased serum ferritin and disappearance of stainable iron in PMNs.
- Phagocytosis of Yersinia enterocolitica by PMNs significantly improved.
- A significant correlation was observed between decreased serum ferritin and enhanced PMN phagocytosis.
- Bacterial killing capacity of PMNs against Y. enterocolitica also improved.
Conclusions:
- rHuEpo therapy effectively reduces iron overload in dialysis patients.
- Improved PMN functions, including phagocytosis and bacterial killing, are associated with rHuEpo treatment.
- rHuEpo therapy holds promise for decreasing bacterial infection incidence in iron-overloaded dialysis patients by enhancing innate immune responses.